SER Serina Therapeutics, Inc. Insider Trading

Director Karen J Wilson buys 10,100 shares at avg $1.76 in June; stock now at $1.92, -75.8% from 52-week high.

Karen J Wilson, a director at Serina Therapeutics, made 2 separate purchases totaling 10,100 shares for $17,749.50 on June 11–12, 2026, establishing an initial position at a blended average price of $1.76. The stock has since appreciated to $1.92 (+17.1% over 30 days), but remains -75.8% from its 52-week high of $7.92 and sits in a deeply depressed valuation range. The company is unprofitable with net income of -$6,898,000 and zero revenue in the latest quarter, though it reported +132.1% annual revenue growth year-over-year. Wilson's prior same-ticker purchases (May 21–22) are not yet measurable at the 90-day mark, and her cross-ticker track record of 2 prior buys provides limited historical context for assessing timing accuracy. This filing documents a director's entry into a position in a pre-revenue biotech-stage company trading near historical lows, but the lack of measurable prior outcomes and the company's fundamentally distressed financial state limit confidence in interpreting the significance of this acquisition.

Director Karen J Wilson purchases 20,000 shares (20.0K shares) for $37,000.00 across two transactions at Serina Therapeutics (SER), establishing first holding.

Karen J Wilson, a Director at Serina Therapeutics, made 2 purchases totaling 20,000 shares for $37,000.00, establishing an initial stake in the company. The purchases occurred at $1.77 on 2026-05-21 and $1.93 on 2026-05-22, with a blended average price of $1.85. This transaction warrants attention given the company's financial profile: net income of $-6.9M in the most recent period and full-year unprofitability, though revenue growth of 132.1% year-over-year indicates accelerating top-line performance. A director purchasing shares for the first time creates a change in insider positioning at a company in growth phase but not yet profitable, meriting investor review of the acquisition's strategic rationale.

Director Richard Peter Marshall bought 12,183 shares at $1.65 in first transaction; stock down 75.0% from 52-week high of $7.92

Director Richard Peter Marshall acquired 12,183 shares at $1.65 on 2026-05-19, representing his first open-market purchase at Serina Therapeutics. The transaction occurs after the stock has declined 75.0% from its 52-week high of $7.92, placing it near the low end of the 52-week range of $1.22–$7.92. The company remains unprofitable with net income of $-6,898,000.00 and zero revenue in the latest quarter, though it reported annual revenue growth of +132.1% year-over-year. The purchase warrants examination of whether it reflects conviction in a turnaround narrative or is simply opportunistic positioning at depressed levels in a cash-burning enterprise.

Director Bailey Gregory bought 3.9K shares of SER at $4.59 on 2024-12-17; stock now at $5.53, up 10.6% in 30 days but down 62.8% from 52-week high.

Bailey Gregory purchased 3,866 shares at $4.59, adding 6.1% to his holdings. The transaction timing follows recent volatility: the stock has gained 10.6% over the past 30 days but remains significantly depressed at -62.8% from its 52-week high of $14.87. Critically, Gregory's prior trades at SER show a mixed track record—only 1 of 5 prior buys generated positive 90-day returns, with three consecutive August-September 2024 purchases largely underwater at the 90-day mark. The company itself presents a mixed fundamental picture: while annual revenue growth reached +317.6%, it remains unprofitable on a full-year basis, with the latest quarter showing only $14,000 in revenue against a $49.2M market cap. This purchase occurs within the context of poor historical execution on this specific ticker and deteriorating full-year profitability, making it insufficient to signal conviction absent additional catalyst visibility.

Director Bailey Gregory bought 1,137 shares of SER at $6.03 on 2024-09-20; stock down 49.6% from 52-week high.

Bailey Gregory, a director at Serina Therapeutics, purchased 1,137 shares at $6.03 on 2024-09-20, increasing his holdings from 62,240 to 63,377 shares. This transaction occurs as the stock trades 49.6% below its 52-week high of $14.87 and has declined 10.8% over the prior 30 days. Gregory's prior trades at this ticker show a pattern of negative near-term returns: his four prior buys at SER (most recent on 2024-08-16) posted 30-day returns of -11.9%, -24.2%, -27.8%, and subsequent outcomes remain unmeasurable. Across his broader cross-ticker trading history, his 19 prior buys averaged -1.6% at 30 days and -2.4% at 90 days, with a 90-day win rate of 18.18%. The company reported annual revenue growth of +317.6% but remains unprofitable on a full-year basis despite posting a $5.2M net income in the latest quarter—a sign of potential volatility in underlying business performance.

Director Bailey Gregory bought 14,388 shares over 2 days for $88,257.39; holdings grew 30.1%, but stock down 55.5% YoY and -19.2% in 30 days.

Bailey Gregory purchased 2 separate tranches totaling 14,388 shares for $88,257.39 on 2024-09-18 and 2024-09-19 at prices of $6.23 and $6.11 respectively, increasing his holdings by 30.1%. However, the context reveals headwinds: the stock currently trades at $6.62, down 55.5% from its 52-week high of $14.87 and down 19.2% over the past 30 days. Gregory's prior trades at this ticker (5 previous buys) have shown consistently negative 30-day returns, ranging from -3.2% to -27.8%, with 0 of 0 prior same-ticker buys well-timed at the 90-day mark. The company generated $51,000 in latest-quarter revenue and reported $5,204,000 net income, but was unprofitable on a full-year basis, creating uncertainty about fundamental sustainability despite 317.6% annual revenue growth.

Director Steven Mintz buys 6,000 shares of Serina Therapeutics at $6.47; stock -57.4% from 52-week high.

Steven Mintz, a Director, purchased 6,000 shares at $6.47 on 2024-09-12, expanding his holdings by 52.4% to 17.4K shares. The stock has declined 11.2% over the preceding 30 days and 45.3% over 90 days, trading at $6.34—well below its 52-week high of $14.87. Within this same ticker, Mintz made five prior purchases on 2024-08-15, all showing a -2.3% return at the 30-day mark; longer-term outcomes remain unmeasurable for those trades. His cross-ticker track record shows zero wins at the 90-day mark across 13 prior buys despite an average 30-day gain of 8.7%, underscoring a pattern of poor timing. The company reported recent quarterly revenue of $51.0K with positive net income of $5.2M, but full-year net income was negative despite 317.6% annual revenue growth, suggesting operational or accounting volatility. This purchase timing—adding to a depressed position amid sustained downward momentum—lacks supporting evidence from the insider's historical execution pattern.

Director Bailey Gregory bought 1,776 shares of SER at $8.25 on 2024-08-20; stock down 45.2% from 52-week high, yet he purchased for fourth consecutive day

Bailey Gregory purchased 1,776 shares at $8.25 on 2024-08-20, marking his fourth consecutive buy at Serina Therapeutics within the past week (purchases on 2024-08-19, 2024-08-16, 2024-08-15, and 2024-08-14). The stock currently trades at $8.15, down 45.2% from its 52-week high of $14.87 and down 14.1% over the past 30 days, suggesting a sustained price decline. His cross-ticker track record shows mixed results: 15 prior buys averaged 4.6% return over 30 days but only 2.5% over 90 days with a 25% win rate, indicating his timing at other securities has not been strong. At Serina specifically, only one prior trade outcome is measurable (a May 2024 buy with +0.8% after 30 days), and his prior same-ticker purchases remain too recent to assess outcomes. The accumulation pattern in the final week of August during pronounced weakness warrants observation as the company navigates year-over-year revenue growth of 317.6% while reporting negative annual net income.

Director Bailey Gregory bought 19,200 shares of SER in 3 transactions (Aug 15-19) for $140,116.48, raising holdings 72.2% to 45,806 shares

Bailey Gregory, a Director, executed 3 separate purchases totaling 19,200 shares for $140,116.48 at prices ranging from $6.65 to $7.93, lifting his post-transaction holdings to 45,806 shares from 26,606 shares (a 72.2% increase). The timing occurred as the stock traded near its 52-week low of $6.42, with the stock currently at $8.25, representing a -44.5% decline from its 52-week high of $14.87 and a -15.0% drop over the prior 30 days. While Serina Therapeutics has demonstrated remarkable annual revenue growth of +317.6%, the company remains unprofitable on a full-year basis despite a positive quarterly net income of $5.2M on revenue of $51.0K. The multi-transaction structure and substantial increase in stake during a period of significant stock weakness warrant investor attention to both the company's underlying business trajectory and the insider's conviction in current valuation levels.

Director MINTZ STEVEN bought 8,943 shares at $6.59 on 2024-08-15 ($58.9K); stock now $8.09, up from lows but -45.6% from 52-week high.

MINTZ STEVEN executed 5 separate purchases totaling 8,943 shares for $58,928.12 at $6.59 on 2024-08-15, moving from a short position (-6,293 shares) to a 2,650-share long position. The purchases occurred while the stock trades at $8.09, up 22.8% from the transaction price but 45.6% below its 52-week high of $14.87. His prior trades at Serina Therapeutics show a 0% win rate at the 90-day horizon (all five prior buys resulted in losses by day 90), and his cross-ticker track record shows a 0.00% 90-day win rate across 8 buys, with average 90-day returns of -21.8%. The company posted strong revenue growth of +317.6% year-over-year but was unprofitable over its most recent full fiscal year, suggesting business expansion into losses rather than profitability gains.